Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu

This article was originally published in The Pink Sheet Daily

Executive Summary

Consolidation could shrink China’s pharmaceutical industry from 4,000 firms today to as few as 1,000 in future, Simcere CEO tells investors at Goldman Sachs conference.

You may also be interested in...



Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda

Continuing its acquisition strategy, Simcere Pharmaceutical Group, one of China's largest branded generics manufacturers, bought a 51 percent stake in Boda Pharmaceutical in a deal valued at $14.8 million (RMB 111 million), Simcere announced Sept. 28

Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda

CEO Ren continues acquisition strategy, giving Simcere control of the entire Chinese injectable edaravone market.

Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda

CEO Ren continues acquisition strategy, giving Simcere control of the entire Chinese injectable edaravone market.

Related Content

Topics

UsernamePublicRestriction

Register

PS066188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel